HUTCHMED (China) ( (HK:0013) ) has shared an update.

HUTCHMED reported pivotal Phase II data for its FGFR1/2/3 inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, showing an independent review objective response rate of 42.5% and a disease control rate of 83.9%. The single-arm China-based trial also delivered a median duration of response of 6.9 months, progression-free survival of 6.9 months and overall survival of 16.6 months, with rapid onset of action and a manageable safety profile marked mainly by elevated liver enzymes and palmar-plantar erythrodysesthesia.

Supported by these data, China’s National Medical Products Administration has accepted and granted priority review to a New Drug Application for fanregratinib in previously treated advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements. If approved, fanregratinib could become an important targeted option for a hard-to-treat biliary tract cancer segment, strengthening HUTCHMED’s oncology portfolio and reinforcing its position in the fast-growing market for precision cancer therapies in China.

The most recent analyst rating on (HK:0013) stock is a Hold
with a HK$21.30 price target.
To see the full list of analyst forecasts on HUTCHMED (China) stock,
see the HK:0013 Stock Forecast page.